Relevance of 68Ga PSMA11 in prostate cancer patient management

Optimal staging is a prerequisite in oncology. All our classification and treatment decisions have been based for decades on Bone and CT scans.

Recently PSMA PET has been shown to really outperform these modalities for both sensitivity and specificity. Therefore should them be thrown away?

Furthermore this has led to a complete change in the landscape: so called N0M0 situations are in fact M1, at relapse we can see spots with low PSA. But what are we doing with these results? Can we extrapolate management from previous imaging? And finally does this results in a better outcome?

This webinar will try to clarify the available evidence and unsolved questions when considering 68Ga PSMA PET imaging in prostate cancer.

Renowned experts of the EAU Section of Oncological Urology (ESOU), EAU Section of Urological Imaging (ESUI) and the EAU Guidelines will share vital research and valuable insights with you in detail.

N. Mottet, Saint-Étienne (FR)
S. Fanti, Bologna (IT)
T. Maurer, Hamburg (DE)

Publication date: April 2021
Available languages: English
Topic: Oncological urology, Urological Imaging
CME: 1 European CME credits (ECMEC)
Duration: Approx. 60 – 90 minutes